Jeffrey Testani, MD, MTR

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Boehringer Ingelheim, Bristol Myers Squibb, Reprieve inc., Sequana Medical, Abbott, Merck
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Boehringer Ingelheim, Bristol Myers Squibb, Cardionomic, MagentaMed, Reprieve inc., FIRE1, Sequana Medical, Merck, Windtree Therapeutics, Precardia, Regeneron, BD, Edwards life sciences, and Lilly.
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    Reprieve inc. Sequana Medical
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Patent
    Ineligible company:
    Yale, Corvidia, Reprieve, Sequana
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
Return to 103 Cardiology Grand Rounds: "Cardio-Renal Syndrome and Diuretic Resistance: Mechanism and Clinical Implications" (051023)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.